HRSA Launches Pilot Program Shifting 340B Drug Discounts to Claim-Based Rebates
Table of Contents
A new model for accessing 340B drug discounts is set to roll out in 2026, prompting concerns about cash flow and administrative burdens for safety-net providers.
The Health Resources and Services Administration (HRSA) announced on October 30th the selection of eight drug manufacturers to participate in its 340B Rebate Model Pilot Program. The program will initially encompass ten widely used drugs, including Eliquis (Bristol Myers Squibb), Enbrel (Immunex), Farxiga (AstraZeneca), Imbruvica (Pharmacyclics), Januvia (Merck Sharp Dohme), Jardiance (Boehringer Ingelheim), Novolog and Fiasp (Novo Nordisk), Stelara (Janssen), and Xarelto (Janssen).
The shift represents a significant change in how hospitals and clinics access 340B discounts. Traditionally, these providers purchase drugs at a discounted rate. Under the new pilot program, they will first pay the wholesale acquisition cost (WAC) and then pursue savings through a claim-based rebate process managed through the Beacon platform, operated by Second Sight Solutions.
“Many 340B Covered Entities have expressed concerns about the ‘time value of money’ implications of the delay in realizing discounts and increased costs resulting from the extra work of submitting for rebates,” a senior official stated. The concern centers on the lag between upfront costs and eventual reimbursements. Second Sight Solutions also manages 340B ESP, the platform used for reporting requirements related to contract pharmacy restrictions, meaning Covered Entities already utilizing ESP will need to create a separate account for the new rebate process.
Participating providers must first register on Beacon, submitting detailed business documentation – including IRS letters, proof of incorporation, and updated W-9 forms – and validating their bank accounts for Automated Clearing House (ACH) payments. The registration requirements differ based on entity type; hospital covered entities only need to register for their parent 340B ID, while grantee covered entities, such as Federally Qualified Health Centers (FQHCs) and Ryan White Clinics, must register each unique 340B ID.
Initial drug purchases eligible for rebates must be made through the Covered Entity’s existing 340B wholesaler account at WAC. Following drug dispensing, providers are required to submit specific claim data codes and fields through Beacon. These requirements differ slightly for medical and pharmacy claims:
Medical Claims:
- 340B ID
- Claim number
- Claim line number
- Date of service
- Health plan name
- Health plan ID
- NDC-11
- Rendering physician NPI
- Quantity
- Healthcare entity NPI
Pharmacy Claims:
- 340B ID
- Date prescribed
- Date of service
- Rx number
- Fill number
- NDC-11
- Quantity dispensed
- Prescriber NPI
- Pharmacy NPI
- Rx BIN and PCN
Accuracy and Cash Flow Considerations
Unlike the current system of upfront discounts, the new model requires providers to upload claim files after dispensing. This places a premium on data accuracy, as errors or duplicates can lead to payment delays or outright denials. While Beacon offers real-time validation, tracking, and reconciliation tools, every step of the claim submission process will be subject to scrutiny from both HRSA and the drug manufacturers.
Beacon has indicated that rebates will typically be processed within ten days of validated claims. However, this turnaround time still introduces a short-term cash flow gap. “Instead of instant savings, expenses are reimbursed only after claims are reviewed and approved,” one analyst noted. This shift could particularly impact smaller clinics, affecting their budgeting and operational flexibility.
Furthermore, providers must prepare for increased diligence when claim errors or mismatches occur. The workflow for resolving delayed rebates now involves coordinating with manufacturers and Beacon support before escalating issues to HRSA.
Preparing for the 340B Rebate Model
The 340B Rebate Model Pilot Program necessitates a reevaluation of administrative and pharmacy workflows. Comprehensive staff training on the new claim requirements, Beacon’s submission process, and reconciliation protocols is crucial. Third-party administrators (TPAs) and Electronic Medical Record (EMR) vendors must ensure data is correctly formatted and transmitted, and staff should be familiar with Beacon’s support materials and troubleshooting resources.
As the pilot program progresses, the insights gained will inform HRSA, 340B Covered Entities, and manufacturers as they consider the potential for broader implementation and expansion in the years to come.
